News headlines about pSivida Corp. (NASDAQ:PSDV) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. pSivida Corp. earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9210633419429 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

pSivida Corp. (NASDAQ:PSDV) traded up 4.96% during mid-day trading on Friday, hitting $1.27. The stock had a trading volume of 198,232 shares. The stock’s market cap is $49.87 million. pSivida Corp. has a 52-week low of $1.03 and a 52-week high of $3.83. The firm has a 50-day moving average of $1.22 and a 200-day moving average of $1.67.

A number of research firms have recently weighed in on PSDV. HC Wainwright set a $5.00 price objective on pSivida Corp. and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Rodman & Renshaw began coverage on pSivida Corp. in a research report on Tuesday, May 30th. They issued a “buy” rating and a $8.00 price objective for the company. FBR & Co reissued an “outperform” rating and issued a $7.00 price objective on shares of pSivida Corp. in a research report on Monday, May 15th. Ladenburg Thalmann Financial Services set a $13.00 price objective on pSivida Corp. and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Finally, Northland Securities set a $10.00 price objective on pSivida Corp. and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $8.60.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at

In other pSivida Corp. news, insider Nancy Lurker bought 56,700 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average price of $1.76 per share, with a total value of $99,792.00. Following the completion of the acquisition, the insider now directly owns 56,700 shares of the company’s stock, valued at approximately $99,792. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.59% of the company’s stock.

About pSivida Corp.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Insider Buying and Selling by Quarter for pSivida Corp. (NASDAQ:PSDV)

Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.